Do you want to buy antibiotics online without prescription? http://buyantibiotics24h.com/ - This is pharmacy online for you!
Letter to the Editor
Accepted August 27, 2008 Published online: September 9, 2008
Neuroaid in Stroke Recovery
Mount Alvernia Hospital, Singapore , Singapore
Stroke is a leading cause of death and disability condition dictated ( table 2 ). The Neuroaid dose received
worldwide  . Many patients only make a partial or poor
was 4 tablets, 3 times per day. Treatment was initiat-
recovery after stroke, and the major burden of stroke is ed between 1 week and 6 months after stroke, and given chronic disability  . To date, no effective treatment has to each patient for 2–3 months.
been found for reducing stroke-induced disabilities.
Cases presented with neurological impairments af-
Neuroaid originates from Traditional Chinese Medi-
fecting motor, balance, speech and visual functions.
cine. It has been developed to aid post-stroke recovery, These were assessed during initial examination and and has recently been approved in 7 countries, includ-
The patients showed a good tolerability to the treat-
Early trials of Neuroaid, performed in China on 605 ment. Only 1 mild adverse event was reported, with pa-
patients in 2000, established its safety and demonstrated
tient No. 4 reporting diarrhea after starting Neuroaid.
a positive effect on the recovery of independence and Treatment was reduced, and then progressively in-motor functions. Patients receiving Neuroaid were creased to full dosage within a week.
found to be 2.4 times more likely to achieve indepen-
On follow-up, all cases reported improvements over
dence at 1 month after stroke than the control group [3, the period in which they received Neuroaid. There were 4] . More recently, safety trials showed that Neuroaid, 6 cases of patients showing full recovery, 3 cases of good taken either alone or in combination with aspirin, does or moderate recovery and 1 case of poor recovery. Sig-not modify hemostasis, hematology and biochemistry nificant improvements were recorded in motor, visual, in normal subjects and stroke patients  . Additional
speech and cognitive functions ( table 1 ). Motor skills:
double-blind randomized placebo-controlled trials are the 8 patients with motor deficits improved in the ongoing in Asia  .
strength of their upper and lower extremities, and their
This is a case description of 10 patients who took ability to walk; motor disabilities fully resolved in 6 pa-
Neuroaid after ischemic stroke onset. All patients were tients. Balance:
the 3 patients showing difficulties in
seen in a private clinic at Mount Alvernia Hospital in their balance recovered. Vision:
the diplopia and hemi-
Singapore and in the Neurology Outpatient Clinic for anopia in 5 patients resolved. Speech:
4 patients report-
ed improvements in speech disabilities, including ex-
Neuroaid was given as an add-on to other medica-
pressive aphasia and anomia; after 3 months, 2 had ful-
tions, including antiplatelet, anticoagulant (warfarin), ly recovered from their speech impairments. lipid-lowering, antihypertensive, diabetic and antide-
The impact of Neuroaid treatment cannot be differ-
pressant medications, which were used as the patient’s entiated from the contribution of natural recovery, med-
Tel. +65 6254 5289, Fax +65 6254 1089, E-Mail firstname.lastname@example.org
blurred vision, right hemianopia; right-sided headache
left hemianopia;short-term memory loss, mild headache
ness, strength 4+/5 LLE, left dysmetria;acute vertigo;diplopia
speech difficulties: mild anomia,expressive aphasia
RUE = Right upper extremities; RLE = right lower extremities; LLE = left lower extremities; LUE = left upper extremities.
ication and physiotherapy effects. However, all cases re-
It is consistent with late-stage recovery data shown in
early clinical trials. Although the exact mechanism is
Interestingly, 3 patients started Neuroaid treatment not well understood, initial laboratory studies suggest
at a later stage of stroke recovery. In particular, patient improvements in brain neuroplasticity and neuropro-No. 8 started Neuroaid 6 months after reaching a pla-
tection. Larger double-blind placebo-controlled studies
teau in his recovery, and after this continued to experi-
will provide more comprehensive data on Neuroaid in
ence improvements in his speech and cognitive abilities.
Another 2 patients (No. 6 and 7) started Neuroaid 1 month after their strokes, and both recovered signifi-cantly.
These findings support the safety of Neuroaid and its
positive effect on the recovery of the post-stroke patient.
M = Morning; N = night; D = once a day; B = twice a day; T = thrice a day.
a Intake for patient No. 2 was D.
b Intake for patient No. 10 was B.
1 Mathers CD, Loncar D: Projections of global
4 Chen C, Venketasubramanian N, Gan R, et
mortality and burden of disease from 2002
al: Danqi jiaonang (DJ): a Traditional Chi-
2 Wolfe CD: The impact of stroke. Br Med Bull
5 CHIMES: Chinese medicine Neuroaid effi-
3 Tang Q: Clinical study report on efficiency
cacy on stroke recovery. http://clinicaltrials.
of danqi piantan capsule in the treatment of
apoplexy due to deficiency of qi and stasis of
6 Gan R, Lambert C, Lianting J, et al: Danqi
Piantan Jiaonang does not modify hemosta-
sis, hematology and biochemistry in normal
subjects and stroke patients. Cerebrovas Dis 2008; 25: 450–456.
RO clustrer KCod ATC1 Substanţă activăDenumire medi Companie APPFormă farmacConcentraţie epret max/ut Pret/mgACTRAPID PE NOVO NORDI SOL. INJ. IN 100UI/mlINSUMAN RAPSANOFI - AVESOL. INJ. IN 100ui/ml-3mlINSUMAN RAPSANOFI - AVESOL. INJ. IN 100ui/ml-5mlA10AB04 INSULINUM LISPRO HUMALOG KWELI LILLY NE SOL. INJ. A10AB05 INSULINUM ASPART NOVORAPID PNOVO NORDI SOL. INJ. IN 100ui/ml - 3mlA10AB06
Engelbrektson AL, Korzenik JR, Pittler A, Sanders ME, Klaenhammer TR, Leyer G and CL Kitts. 2009. Probiotics to minimize the disruption of faecal microbiota in healthy subjects undergoing antibiotic therapy. J Med Microbiol 58: 663-670. Engelbrektson, A.L., Korzenik, J.R., Sanders, M.E., Clement, B.G., Leyer, G., Klaenhammer, T.R., & Kitts, C.L., (2006). Analysis of treatment effects on the mi